Drug firm, Wockhardt has reported a net profit of Rs 53.80 crore for the second quarter ended September 30, 2011. It had posted a net loss of Rs 67.86 crore for the same quarter last fiscal. The company’s total income has increased by 33.63% at Rs 640.73 crore for Q2FY12 as compared to Rs 479.49 crore for Q2FY11.
The group has reported a consolidated net profit of Rs 127.58 crore for the quarter under teview on improved sales in all markets led by the US. The company had posted a net loss of Rs 96.68 crore for the corresponding quarter previous year.
Wockhardt USA reported a sales growth of 49% with its prime products improving market share in a highly competitive market scenario. There were three abbreviated new drug application (ANDA) filings and four approvals for the quarter, the company said.
The company's India business grew by 13.5% in the second quarter this fiscal, capturing a market share of 2.03% as compared to 1.94% last year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.35 |
Dr. Reddys Lab | 1392.15 |
Cipla | 1510.05 |
Lupin | 2218.50 |
Zydus Lifesciences | 977.55 |
View more.. |